Licences should enable potentially millions of people living in areas most impacted by HIV to access this innovative prevention medicine through low-cost generic manufacturers
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X join ARCH as new additional investors
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir
Aimed at improving patient outcomes and increasing connectivity for more efficient monitoring In hospitals and homes
Allegra-D had U.S. retail sales of approximately $45 million as of May 2022 according to IRI.
ExoBrite antibody conjugates are validated and optimized for bright and specific detection of exosome markers
Subscribe To Our Newsletter & Stay Updated
